首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3487997篇
  免费   282905篇
  国内免费   14593篇
耳鼻咽喉   48462篇
儿科学   106933篇
妇产科学   91282篇
基础医学   546979篇
口腔科学   96880篇
临床医学   308370篇
内科学   618217篇
皮肤病学   93045篇
神经病学   297935篇
特种医学   138869篇
外国民族医学   453篇
外科学   543370篇
综合类   107087篇
现状与发展   24篇
一般理论   2262篇
预防医学   284315篇
眼科学   79626篇
药学   242983篇
  23篇
中国医学   10347篇
肿瘤学   168033篇
  2021年   54914篇
  2020年   35040篇
  2019年   58025篇
  2018年   70835篇
  2017年   54089篇
  2016年   59844篇
  2015年   73981篇
  2014年   108169篇
  2013年   173358篇
  2012年   90088篇
  2011年   89158篇
  2010年   115510篇
  2009年   120724篇
  2008年   77092篇
  2007年   80620篇
  2006年   91464篇
  2005年   86784篇
  2004年   89024篇
  2003年   80385篇
  2002年   70698篇
  2001年   109274篇
  2000年   102388篇
  1999年   101323篇
  1998年   65231篇
  1997年   63132篇
  1996年   60647篇
  1995年   56092篇
  1994年   50324篇
  1993年   47019篇
  1992年   71714篇
  1991年   68015篇
  1990年   64993篇
  1989年   64335篇
  1988年   60216篇
  1987年   58840篇
  1986年   56328篇
  1985年   55964篇
  1984年   50483篇
  1983年   45770篇
  1982年   42318篇
  1981年   39785篇
  1980年   37627篇
  1979年   42935篇
  1978年   37352篇
  1977年   34266篇
  1976年   31033篇
  1975年   30688篇
  1974年   32403篇
  1973年   31074篇
  1972年   29501篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
13.
14.
Interstitial cystitis/bladder pain syndrome (IC/BPS) and vulvodynia are chronic pain syndromes that appear to be intertwined from the perspectives of embryology, pathology and epidemiology. These associations may account for similar responses to various therapies.  相似文献   
15.
Antibody-mediated rejection is a major complication in renal transplantation. The pathologic manifestations of acute antibody-mediated rejection that has progressed to functional impairment of a renal transplant have been defined in clinical biopsy specimens. However, the initial stages of the process are difficult to resolve with the unavoidable variables of clinical studies. We devised a model of renal transplantation to elucidate the initial stages of humoral rejection. Kidneys were orthotopically allografted to immunodeficient mice. After perioperative inflammation subsided, donor-specific alloantibodies were passively transferred to the recipient. Within 1 hour after a single transfer of antibodies, C4d was deposited diffusely on capillaries, and von Willebrand factor released from endothelial cells coated intravascular platelet aggregates. Platelet-transported inflammatory mediators platelet factor 4 and serotonin accumulated in the graft at 100- to 1000-fold higher concentrations compared with other platelet-transported chemokines. Activated platelets that expressed P-selectin attached to vascular endothelium and macrophages. These intragraft inflammatory changes were accompanied by evidence of acute endothelial injury. Repeated transfers of alloantibodies over 1 week sustained high levels of platelet factor 4 and serotonin. Platelet depletion decreased platelet mediators and altered the accumulation of macrophages. These data indicate that platelets augment early inflammation in response to donor-specific antibodies and that platelet-derived mediators may be markers of evolving alloantibody responses.  相似文献   
16.
17.
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (= 768 SMV/PR,= 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity.  相似文献   
18.
19.
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号